Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ritter Pharmaceuticals Inc    RTTR

RITTER PHARMACEUTICALS INC

(RTTR)
  Report  
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

RITTER PHARMACEUTICALS INC : Other Events, Financial Statements and Exhibits (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/11/2019 | 05:24pm EDT

Item 8.01. Other Events.

On July 11, 2019, Ritter Pharmaceuticals, Inc. (the "Company") issued a press release announcing that it had received written notice from Nasdaq that the Company's minimum bid price deficiency has been cured and that the Company is in compliance with all applicable listing standards. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits.



Exhibit No.   Description
99.1            Press Release dated July 11, 2019, entitled "Ritter Pharmaceuticals
              Regains Compliance with Nasdaq's Minimum Bid Price Requirement -
              Ritter Shares Will Continue to Trade on the Nasdaq Capital Market"











Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



  RITTER PHARMACEUTICALS, INC.

  By:    /s/ Andrew J. RitterName:  Andrew J. Ritter
  Title: Chief Executive Officer



Date: July 11, 2019

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on RITTER PHARMACEUTICALS INC
07/12RITTER PHARMACEUTICALS : Regains Compliance with Nasdaq's Minimum Bid Price Requ..
AQ
07/11Ritter Pharmaceuticals Regains Compliance with Nasdaq's Minimum Bid Price Req..
GL
07/11RITTER PHARMACEUTICALS INC : Other Events, Financial Statements and Exhibits (fo..
AQ
07/03RITTER PHARMACEUTICALS : Announces Last Patient Last Visit in its Phase 3 'Liber..
AQ
07/02Ritter Pharmaceuticals Announces Last Patient Last Visit in its Phase 3 &ldqu..
GL
07/01RITTER PHARMACEUTICALS INC : Notice of Delisting or Failure to Satisfy a Continu..
AQ
06/21RITTER PHARMACEUTICALS : provides-phase-3-liberatus-clinical-trial-and-regulator..
AQ
06/20Ritter Pharmaceuticals Provides Phase 3 Liberatus Clinical Trial and Regulato..
GL
06/17RITTER PHARMACEUTICALS INC : Submission of Matters to a Vote of Security Holders..
AQ
05/31RITTER PHARMACEUTICALS : Shares New Market Research Illuminating the Life Challe..
AQ
More news
Financials (USD)
Sales 2019 -
EBIT 2019 -17,7 M
Net income 2019 -17,6 M
Debt 2019 -
Yield 2019 -
P/E ratio 2019 -0,90x
P/E ratio 2020 -1,98x
Capi. / Sales2019 infx
Capi. / Sales2020 infx
Capitalization 8,95 M
Chart RITTER PHARMACEUTICALS INC
Duration : Period :
Ritter Pharmaceuticals Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RITTER PHARMACEUTICALS INC
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 6,50  $
Last Close Price 0,99  $
Spread / Highest target 607%
Spread / Average Target 557%
Spread / Lowest Target 506%
EPS Revisions
Managers
NameTitle
Andrew J. Ritter President, CEO, Secretary & Director
Ira E. Ritter Executive Chairman & Chief Strategic Officer
John W. Beck Chief Financial Officer
Diane J. Plotkin Vice President-Clinical Development
Noah J. Doyle Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
RITTER PHARMACEUTICALS INC65.00%9
GILEAD SCIENCES3.98%82 702
VERTEX PHARMACEUTICALS5.08%44 598
REGENERON PHARMACEUTICALS-20.18%32 544
GENMAB14.24%11 908
SAREPTA THERAPEUTICS INC36.77%11 068